Sinobiomed’s (OTCBB: SOBM) recombinant Batroxobin (rBAT) is in its Phase IIb trials for 328 patients. Results are expected before year’s end. A company news release says international interest from government and organizations would grow significantly if the product proceeds to Phase III clinical trials.
“[We have] already received indications of interest from global pharmaceutical companies for joint development, marketing and production,” the release states.
Clinical trials for Sinobiomed’s recombinant malaria candidate vaccine are set to begin before the end of the 3rd Quarter. The tests are tentatively planned to take place at Mahidol University in Bangkok, Thailand.
Batroxobin is produced through genetic engineering of the venom, which reduces the risk of biological contaminates associated with natively extracted batroxobin.
Sinobiomed also has majority ownership in a skincare and cosmetics line, through Shanghai Wanxing Bioscience Cosmetics. Sales of more than $3 million over the coming year are expected, with anticipated gross profit margins greater than 70 percent.
Let us hear your thoughts below: